Study of Durvalumab in Combination with Platinum and Etoposide for the First Line Treatment of Patients with Extensive-stage Small Cell Lung Cancer - LUMINANCE

Study identifier:D419QC00007

ClinicalTrials.gov identifier:NCT04774380

EudraCT identifier:2020-005537-32

CTIS identifier:N/A

Recruitment Complete

Official Title

A Phase IIIb, Single-arm, Multi-center, International Study of Durvalumab in Combination with Platinum and Etoposide for the First Line Treatment of Patients with Extensive-stage Small Cell Lung Cancer (LUMINANCE)

Medical condition

Extensive-stage Small Cell Lung Cancer

Phase

Phase 3

Healthy volunteers

No

Study drug

Durvalumab, Cisplatin, Carboplatin, Etoposide

Sex

All

Actual Enrollment

152

Study type

Interventional

Age

18 Years - 130 Years

Date

Study Start Date: 11 Nov 2021
Primary Completion Date: 12 Jun 2023
Estimated Study Completion Date: 31 Dec 2024

Study design

Allocation: Non-randomized
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Jul 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria